Bachert, Claus
Marple, Bradley
Schlosser, Rodney J.
Hopkins, Claire
Schleimer, Robert P.
Lambrecht, Bart N.
Bröker, Barbara M.
Laidlaw, Tanya
Song, Woo-Jung
Article History
Accepted: 9 September 2020
First Online: 29 October 2020
Competing interests
: C.B. serves in advisory boards for AstraZeneca, GlaxoSmithKline, Mylan, Novartis and Sanofi-Aventis. R.J.S. has served as a consultant for GlaxoSmithKline, Healthy Humming, Optinose, Sanofi, and Stryker and has received grant support from AstraZeneca, Optinose and Stryker. C.H. has served on advisory boards for AstraZeneca, Olympus, Sanofi and Smith & Nephew. R.P.S. is a consultant for Actobio Therapeutics, Allakos, Aqualung Therapeutics Corp., Astellas Pharm. Inc., AstraZeneca/Medimmune, Aurasense, BioMarck, Celgene Corp., Exicure, Genentech, Genzyme/Sanofi Corp., GlaxoSmithKline, Intersect ENT, Lyra Therapeutics, Merck, Otsuka, and Sanofi and he owns stocks or stock options for Allakos, Aqualung Therapeutics Corp., Aurasense, BioMarck, and Exicure. Furthermore, he owns Allakos Siglec-8 and Siglec-8 ligand related patents; as a result of the Allakos licensing agreement, per Johns Hopkins University policy, he may be entitled to a share of future royalties regarding the sale of Siglec-8 related products, although no such royalties exist at the time of writing. T.L. has served on scientific advisory boards for GlaxoSmithKline, Optinose, Regeneron and Sanofi-Genzyme. B.N.L. serves in advisory boards for GlaxoSmithKline, Novartis, OncoArendi and Argenx. All other authors declare no competing interests.